This CPB has been revised to state that: (i) leuprolide is considered medically necessary for the treatment of endometrial stromal sarcoma; (ii) leuprolide is considered experimental and investigational for the treatment of acute intermittent porphyria, benign metastasizing leiomyoma, and borderline leiomyosacroma, and (iii) histrelin acetate implant is considered experimental and investigational for the treatment of gender dysphoria. This CPB is revised to state that Supprelin LA histrelin acetate subcutaneous implant, triptorelin (Trelstar), and triptorelin extended-release (Triptodur) are considered medically necessary for the following indications: (i) to suppress onset of puberty in transgender adolescents; (ii) for female to male transgender persons, to stop menses prior to testosterone treatment and to reduce estrogens to levels found in biological males; and (iii) to reduce testosterone levels in male to female transgender persons. This CPB is revised to state that goserelin (Zoladex) is considered medically necessary to suppress onset of puberty in transgender adolescents.